Vanda’s Tradipitant Gets CRL In Gastroparesis But Another NDA Filing Is Still On

The company will file a new drug application with the US FDA by the end of the year for tradipitant in a different indication, motion sickness.

FDA rejected Vanda's NDA • Source: Shutterstock

Vanda Pharmaceuticals’s new drug application (NDA) for tradipitant for the treatment of symptoms in gastroparesis was rejected by the US Food and Drug Administration, but the company still intends to file tradipitant in a different indication – motion sickness – by the end of the year.

Key Takeaways
  • The FDA rejected Vanda’s NDA for tradipitant for the treatment of symptoms in gastroparesis due to concerns about safety and efficacy.
  • Vanda has already sued the...

The company announced receipt of a complete response letter (CRL) for tradipitant in gastroparesis on 19 September. The CRL was expected because Vanda already told investors that the FDA had...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Complete Response Letters

What Information Does US FDA Need For Stealth’s Elamipretide After CRL?

 
• By 

The agency said it will consider knee extensor muscle strength as a potential intermediate clinical endpoint to support accelerated approval, but Stealth CEO Reenie McCarthy said announcing it via complete response letter is confusing and inefficient.

EU Authorization Before US? Biologics Manufacturing Is Likely To Blame

 

In the infrequent cases when EU authorization precedes US FDA approvals of new products, biologics manufacturing issues are usually to blame, a Pink Sheet analysis found.

Another Regeneron CRL Prompts Regulatory Operations Questions

 

CEO Len Schleifer said during the company’s first quarter earnings call that most of the complete response letters the company has received related to third-party suppliers, not efficacy or safety.

US FDA Miss On Stealth’s Elamipretide Boosts Signal Of Broader Delays Due To Staff Cuts

 
• By 

Failing to meet the 29 April user fee date for the Barth syndrome treatment, and CDER’s request for a delay in responding to Vanda’s appeal of a tradipitant complete response letter, suggest a slowdown in review work due to layoffs and other recent changes.

More from Product Reviews

US FDA Meeting Drought Ends … With A Vengeance

 

The first 100 days of the Trump Administration were notable for an extraordinary decline in the number of public meetings hosted by the US Food and Drug Administration. But the schedule changed quickly.

EU CHMP Opinions And MAA Updates

 

This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.

HHS Rescinds COVID-19 Vaccine Advice, Usurping US CDC Role

 
• By 

By stepping into the role of the Centers for Disease Control and Advisory Committee on Immunization Practices, HHS Secretary Robert F. Kennedy Jr. is causing further confusion and uncertainty about vaccine policy, experts say.